This paper presents a DEA (Data Envelopment Analysis)/ Malmquist index methodology for measuring the R&D efficiency change of the Japanese pharmaceutical industry. Letting each of ten firms each year be a separate DMU (Decision-Making Unit) and employing one input and three outputs in the DEA, and using the cumulative frontier shift component on average proposed in the Malmquist index analysis, we quite obviously show the industry-wide R&D efficiency change for the period 1982-2001. The results empirically reveal that the R&D efficiency of the Japanese industry, which has seemed elusive, has surely gotten worse almost monotonically for these twenty years at least as to the pharmaceutical one.
INTRODUCTION
This paper measures R&D efficiency of Japanese pharmaceutical firms and examines how R&D efficiency at the industry level has changed over time. R&D in firms, that can be considered as a stage prior to production, would be as important as production. But we have not quantitatively analyzed R&D efficiency so much as productivity. The lack of how to measure R&D efficiency would be the main reason. In considering the input and output of R&D, we cannot immediately specify what to be as the output, compared with R&D investment as the input. Geisler (1995) and Brown and Svenson (1998) list published articles, patents, new products, etc. as the output. This multiplicity of the output prevents from analyzing R&D efficiency by means of the ordinary production function, i.e., parametric, approach. After all, true efficiency in R&D has yet been elusive.
Thus it is not easy to measure R&D efficiency, so that we have seldom observed its chronological transition at the industry level. Has it gradually gotten better as incorporating some innovations into process like productivity could be expected? For the recent Japanese industry, it might not or might have even worsened (Sakakibara and Tsujimoto, 2003) . For also the pharmaceutical industry in the world, it is said that the R&D efficiency is recently in decline (Tollman et al., 2004) . Taking up the Japanese pharmaceutical industry, we verify whether the R&D efficiency has gotten better or worse for the latest twenty years.
In order to analyze the R&D efficiency, we employ DEA (Data Envelopment Analysis) (e.g., Charnes et al., 1994 , Cooper et al., 2000 . DEA is a non-parametric method that can measure the relative efficiency, i.e., DEA efficiency, of objects called DMUs (DecisionMaking Units) with multiple inputs and multiple outputs. Although DEA could be applied to various fields other than the standard efficiency analysis (e.g., Hashimoto and Ishikawa, 1993, Hashimoto, 1996) , the DEA characteristic that can deal with even multiple outputs has enabled to measure the efficiency of a variety of DMU sets in also the original efficiency analysis. For example, Nasierowski and Arcelus (2003) recently measure the efficiency of 45 national innovation systems with two inputs and three outputs using DEA. However, we can find no DEA analyses of firms' R&D efficiency except for Honjo and Haneda (1998) . They try to analyze the R&D efficiency of fourteen Japanese pharmaceutical firms with one input and two outputs for the period 1977-1991. Refining their analyses, we also preparatorily do DEA analyses using the panel data of ten pharmaceutical firms for 1982-2001. But we should note that the ordinary DEA cannot analyze as taking the DEA efficiency frontier shifting over time into consideration.
Then, we introduce DEA/ Malmquist index analysis (e.g., Färe et al., 1998 , Thanassoulis, 2001 ) to examine time series change in R&D efficiency at the industry level. The Malmquist index can measure the ratio of DEA efficiencies in two different time periods with shifting DEA efficiency frontiers. Although we recently have some DEA/ Malmquist index applications, most of which are applied to productivity like González and Gascón (2004) . The Malmquist index can be decomposed into two components: "catch-up" and "frontier shift". The former measures how much closer to the frontier a DMU, i.e., a firm, moves, while the latter does the movement of the frontier. Since the frontier is composed of the DEA efficient DMUs among all the firms in a time period, the frontier shift means the change at the industry level, not at the firm one. Using this frontier shift, we devise to quite obviously display the R&D efficiency change of the Japanese pharmaceutical industry for the period 1982-2001.
DATA TO MEASURE R&D EFFICIENCY
To DEA-analyze the R&D efficiency and its change of the Japanese pharmaceutical industry, we provide four data panels as follows: Each panel is ten firms × twenty years. That is, the sample period is the latest 1982-2001 and the ten pharmaceutical firms are Takeda, Sankyo, Yamanouchi, Daiichi, Eisai, Shionogi, Fujisawa, Chugai, Tanabe and Yoshitomi. They are all big enterprises driving R&D and seem homogeneous as professional-medicine makers. Although we first took the biggest thirteen pharmaceutical firms of Japan into consideration, Kyowa-Hakko and Meiji-Seika were excluded because each of their medicine sales did not reach to fifty percent of its whole sales. We also excluded Taisho because of its characteristic as a popular-medicine maker peculiar vs the other firms.
DEA relatively evaluates how efficiently DMUs convert multiple inputs into multiple outputs. That is, any DMU producing more outputs with fewer inputs is judged relatively efficient. In DEA-analyzing the R&D efficiency of pharmaceutical firms as the DMUs, we can straightforward list R&D expenditure (billion yen a year) as the input. As the multiple outputs, we consider the following three: We first list patents (the number of patent applications publicly published a year) as a proxy of invention. R&D activities in firms can be divided into two: one aiming at "product innovation" and the other aiming at "process innovation". While the former contributes sales increase through product discrimination, the latter does profit increase through cost reduction (Odagiri, 1987) .
Corresponding to these respectively, we list pharmaceutical sales (ten billion yen a year) and operating profit (billion yen a year) as the additional outputs. We collect annual data to the one input and three outputs, for the ten firms in the period 1982-2001, from Data Book (Tokyo: Japan Pharmaceutical Manufacturers Association) and NEEDS Database (Tokyo: Nihon Keizai Shimbun, Inc.). The four indicators except for patents are all deflated to the 2001 value.
PRELIMINARY DEA ANALYSES OF R&D EFFICIENCY
We here apply the data collected to a DEA model measuring the relative DEA efficiency of target DMU j 0 , h j 0 (0 ≤ h j 0 ≤ 1). We employ the CCR (Charnes, Cooper and Rhodes, 1978) model, and its input-oriented and envelopment form is formulated as the following LP (Linear Programming):
where θ, λ j , s + r , s − i = decision variables to LP, y rj = the amount of output r from DMU j, x ij = the amount of input i to DMU j, n = the number of DMUs, t = the number of outputs, m = the number of inputs, = a positive non-Archimedean infinitesimal. We can find DEA efficiencies of all the DMUs by solving LP (1) n times, setting each DMU as target DMU j 0 in turn. Here, DMU j 0 with the minimum h *
Three preliminary DEA analyses of the ten pharmaceutical firms are shown in Appendix. We should note the following: First, we employ the CCR model assuming the constant returns-to-scale, not the variable returns-to-scale, because the ten sample firms are all big enterprises and can be regarded comparable under the assumption (see Appendix) . Second, as data measuring the R&D efficiency, we apply input and output data of the same year, not using the input data of a year together with the output data of some years later. Surely, the effect of input would emerge on the output some time later. However, we have no knowledge of how the delay is. Therefore, we might had better consider that the R&D efficiency measured here means the efficiency of rather the R&D sector in firms, that must be settled an account by the annual data, than the R&D activity itself.
From the results of DEA analyses, the R&D efficiency of Japanese pharmaceutical firms do not seem to have gotten better for the period 1982-2001 at all. But these analyses are all at the firm level, and cannot exactly grasp how the R&D efficiency of the pharmaceutical industry has changed in this period. This is a limit of the ordinary DEA single-handed analyses.
CHANGE IN R&D EFFICIENCY FOR 1982-2001
To quantitatively show the R&D efficiency change of the industry for 1982-2001, we here introduce the DEA/ Malmquist index analysis and apply the same data collected.
DEA/ Malmquist Index Analysis
DEA/ Malmquist index analysis measures the Malmquist (productivity) index (Malmquist, 1953 , Caves et al., 1982 in the DEA frame:
In Figure 1 , a single input and output DEA case, DMU j 0 being evaluated was at point A in period α and line OCD shows the then CCR DEA efficiency frontier. Suppose that in period β (β > α), DMU j 0 has moved to point B and the frontier itself has also shifted to line OEF. DEA efficiency change of DMU j 0 can be measured by the ratio of DEA efficiency in period β to that in period α, but the frontier has shifted, so that we compute the geometric mean of ratios as to the two frontiers in periods α and β. This is the DEA (CCR input oriented)/ Malmquist index of DMU j 0 between periods α and β
Here, M I > 1 means gain in DEA efficiency of DMU j 0 from period α to β, while M I = 1 and M I < 1 mean the status quo and loss respectively. Transforming formula (2), Malmquist index can be decomposed into two components as follows:
As each term of formula (3) shows, CU indicates Catch-Up index, i.e, CU > 1 means that DMU j 0 has moved closer to the period β frontier than to the period α one. CU = 1 and CU < 1 mean that it has the same distance and that it has moved farther, respectively. F S indicates Frontier Shift index, and F S > 1 means gain in DEA efficiency frontier shift from period α to β measured from the location of DMU j 0 , i.e., the frontier has moved so as to have the more output with the fewer input as shown in Figure 1 . F S = 1 and F S < 1 mean no change and loss respectively.
Since P E/P A in Figure 1 is, for example, the (radial) DEA efficiency of the period α DMU j 0 measured by means of the period β frontier, we denote it as θ[D α , F β ]. Then from formula (4),
In LP (1) 
this forms the DEA exclusion model (Andersen and Petersen, 1993) . Finally, we can obtain θ[D β , F α ] by also the DEA exclusion model (7) exchanged α and β.
Cumulative Malmquist Index
Applying the data to models (6) and (7), and through formula (5) Table 1 shows that the R&D efficiency of Japanese pharmaceutical firms has gotten worse in average at the annual rate 4.7% for [1982] [1983] [1984] [1985] [1986] [1987] [1988] [1989] [1990] [1991] [1992] [1993] [1994] [1995] [1996] [1997] [1998] [1999] [2000] [2001] , and has in year 2001 dropped to under 40% of the start year 1982. This implies a big loss in firms' R&D efficiency. We should note that all the ten firms have this decreasing R&D efficiency. The worst for this period would be Chugai and Fujisawa while the last worst, Takeda. Since the annual catch-up rate on average in Table 2 is 0.993 (nearly 1), we find that the Malmquist (Table 1) would depend much more on the frontier shift (Table 3) than the catch-up (Table 2) .
The catch-up measures how much closer to the yearly R&D efficiency frontier a firm moves. For only the catch-up, Takeda, Daiichi and Tanabe have gotten even better for this period (Table 2 ). The cumulative catch-up is the ratio of R&D efficiency of a firm in year β to that in year 1982. Therefore, in Table A1 , the cross-section DEA efficiency of a year divided by that of year 1982 is the catch-up value of the year in Table 2 . That is, for Sankyo, the values in Tables 2 and A1 are equal, and for Daiichi, for example, the values in Table 2 do not exceed 1/0.67 = 1.501, i.e., its upper limit.
Picking up columns from Tables 1-3 , we can draw a graph of the three cumulative indices for each firm. Figure 2 for Sankyo and Figure 3 for Daiichi are examples: In Figure 2 , the catch-up shows that Sankyo has been on the R&D efficiency frontier from the start year 1982 to 1998. The Malmquist, that has been equal to the frontier shift for these years, has in year 2001 gone worsened to 25.4% of the start year. For Daiichi (Figure  3) , as is mentioned before, the catch-up has gotten better since the start year and it has reached to the upper limit in years 1985-1987 and 1989 . The cumulative Malmquist indices are also over 1 for [1985] [1986] [1987] [1988] [1989] , so that this shows that the R&D efficiency of Daiichi has improved for this period compared to the start year. In this way, we can quantitatively show the chronological changes in a firm's R&D efficiency using the three cumulative indices.
R&D Efficiency Loss by the Industry
The cumulative frontier shift index indicates the move of the industry's R&D efficiency frontier from the viewpoint (location) of each firm. Therefore, the frontier shift on average (Table 3) could be an appropriate indicator to measure the R&D efficiency change at the industry level. The annual change rate 0.960 means that the R&D efficiency of the Japanese pharmaceutical industry has worsened at the annual rate 4.0% for 1982-2001. That is, the great R&D efficiency frontier shift reverse to as shown in Figure 1 has occurred. Figure 4 is a graph of the cumulative frontier shift on average in Table 3 . It shows that the R&D efficiency of the industry has gotten worse to about 70% of the start year 1982 just in year 1984, and has finally dropped to 45.8% in year 2001 via the lowest 38.9% in 2000. Although there are observed the recoveries in years 1993 and 2001, we must say that the industry's R&D efficiency has almost monotonically been decreasing throughout the period. Thus, we could quite obviously show how the industry-wide R&D efficiency has changed, which implies the great loss in R&D efficiency by the Japanese pharmaceutical industry for the period 1982-2001.
SUMMARY AND CONCLUSIONS
This study presented a DEA/ Malmquist index methodology for measuring the R&D efficiency change at the industry level. Using the cumulative frontier shift index proposed in the methodology, we could quantitatively show the time series change in the R&D efficiency of the Japanese pharmaceutical industry for the period 1982-2001. We here found the great R&D efficiency loss by the industry throughout the period and that the industry's R&D efficiency had dropped in year 2001 to even under fifty percent of the start year 1982.
Since year 1982, why has annually each firm continued to enormously invest in the R&D in spite of the decreasing efficiency? Haneda and Odagiri (1998) indicate that R&D investment affects the value of firm. Because of such factors other than efficiency, the firm might have to continue to invest in R&D. Whether this is true, and whether the recent loss in R&D efficiency comes under the other industries are up to the further studies. In also these study fields, the methodology presented in this paper would be valid to examine them.
Appendix
Solving DEA model (1) with one input and three outputs (m = 1, t = 3), we obtain DEA efficiencies h * j 0 shown in Tables A1-A3 . In all these Tables, value 1 indicates DEA efficient, including no weakly DEA efficient DMUs. We should here notice rather the location of value 1 than the DEA efficiency values themselves. Table A1 shows the results of twenty DEA cross-section analyses with ten DMUs (n = 10), i.e., the cross-section DEA by year, treating each firm as a separate DMU. It is noteworthy that Takeda and Yoshitomi, respectively the largest and the smallest scaled firms measured by the R&D expenditure, both are judged DEA efficient in multiple time periods. This affirms the employment of CCR model assuming the constant returns-to-scale. We find that Sankyo would have been most efficient in R&D because it is judged DEA efficient in seventeen years among the twenty. On the contrary, Eisai has never been DEA efficient for these twenty years. Table A2 shows the results of ten DEA time series analyses with twenty DMUs (n = 20), i.e., the time series DEA (Cooper et al., 1995, Hashimoto and Kodama, 1997) by firm, treating each year as a separate DMU. We find that all the firms have their own DEA efficient years in the first two years, 1982-1983 . And only three firms, Takeda, Sankyo and Yoshitomi, have them in also the last half of the period, 1992-2001. There are no firms having them in the third quarter of the period, 1992-1996. Table A3 shows 
